All too often, decentralized clinical trials (DCTs) are characterized as 'site-less trials'. Yet, the reality is that DCT strategies can empower sites to reach more patients, decrease enrollment timelines, and capture more frequent data through remote patient monitoring.
Thus, we invite you to join Medable's site advisory council and DCT experts as they use real word examples to show how weaving DCT strategies into protocol design empowers sites to streamline, improve, and expand their capabilities. Attendees will walk away with an understanding of how to:
Alison (Ali) Holland is Head of Decentralized Clinical Trials at Medable and is chartered to design and expand the end-to-end capabilities.
As Chief Scientific Officer, Dr. Pamela Tenaerts oversees Medable’s clinical research department to help identify, develop and implement...